Related Experiment Video
Updated: Jul 8, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
Octreotide acetate in dominant cystoid macular dystrophy
B F Hogewind1, G Pieters, C B Hoyng
1University Medical Centre St Radboud, Nijmegen, Gelderland, The Netherlands. b.hogewind@ohk.umcn.nl
Purpose:
Dominant cystoid macular degeneration (DCMD) is an autosomal dominant trait of cystoid macular edema with poor visual prognosis. Until now, no efficient treatments for DCMD have been reported. The authors evaluated a somatostatin-analogue (octreotide acetate) as treatment for DCMD.
Methods:
The authors treated four patients with early DCMD by intramuscular longacting octreotide acetate, 20 mg every 4 weeks for 1 year. In addition to general ophthalmologic examination the authors performed fluorescein angiography (FA) before and after treatment.
Results:
Seven out of eight eyes showed improvement on FA and stabilization of visual acuity.
Conclusions:
Somatostatin-analogues may reduce cystoid edema in DCMD and may thus prevent disease-related visual loss.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Diabetic Retinopathy
